- Home
- ELAN vs MRNA Comparison
ELAN vs MRNA Comparison
Compare ELAN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAN
- MRNA
- Stock Information
- Founded
- ELAN 1954
- MRNA 2010
- Country
- ELAN United States
- MRNA United States
- Employees
- ELAN N/A
- MRNA N/A
- Industry
- ELAN Biotechnology: Pharmaceutical Preparations
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELAN Health Care
- MRNA Health Care
- Exchange
- ELAN Nasdaq
- MRNA Nasdaq
- Market Cap
- ELAN 10.3B
- MRNA 9.2B
- IPO Year
- ELAN 2018
- MRNA 2018
- Fundamental
- Price
- ELAN $22.13
- MRNA $23.60
- Analyst Decision
- ELAN Buy
- MRNA Hold
- Analyst Count
- ELAN 9
- MRNA 13
- Target Price
- ELAN $21.13
- MRNA $33.91
- AVG Volume (30 Days)
- ELAN 5.9M
- MRNA 13.0M
- Earning Date
- ELAN 11-05-2025
- MRNA 11-06-2025
- Dividend Yield
- ELAN N/A
- MRNA N/A
- EPS Growth
- ELAN N/A
- MRNA N/A
- EPS
- ELAN 0.07
- MRNA N/A
- Revenue
- ELAN $4,591,000,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- ELAN $5.77
- MRNA N/A
- Revenue Next Year
- ELAN $4.96
- MRNA $10.38
- P/E Ratio
- ELAN $314.23
- MRNA N/A
- Revenue Growth
- ELAN 3.08
- MRNA N/A
- 52 Week Low
- ELAN $8.02
- MRNA $22.28
- 52 Week High
- ELAN $23.09
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- ELAN 56.25
- MRNA 42.30
- Support Level
- ELAN $20.95
- MRNA $24.18
- Resistance Level
- ELAN $22.22
- MRNA $25.06
- Average True Range (ATR)
- ELAN 0.87
- MRNA 1.41
- MACD
- ELAN -0.14
- MRNA -0.19
- Stochastic Oscillator
- ELAN 57.74
- MRNA 25.10
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.